PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements Korea Free Trade Agreement: intellectual property, market access and public health Trans-Pacific Strategic Economic Partnership Agreement (TPP): intellectual property issues Special 301 submission Preference Program Reform International market access and intellectual property issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| LEA FISHER | — |
| DAVID KORN | — |
| MATTHEW L SULKALA | — |
Copyright/Patent/Trademark CPT
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 628, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings: false patent marking H.R. 5980, Bring Jobs Back to America: Strategic Manufacturing & Job Repatriation Act: publication of patent applications and the economy H.R. 6352, Patent Lawsuit Reform Act of 2010: false patent marking H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 299, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 1315, Drug Price Competition Act of 2009: 180-day exclusivity issues S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements International intellectual property policy issues Biopharmaceutical innovation policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID BOYER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS New | — |
| LEA FISHER | — |
| JAMES BRYANT HALL | — |
| DAVID KORN | — |
| TOM MOORE | — |
| BRIAN NAGLE | — |
| ANNE PRITCHETT | — |
| RICHARD SMITH | — |
| MATTHEW L SULKALA | — |
| STEVE TILTON | — |
Health Issues HCR
H.R. 422, Heart Disease Education, Analysis Research, and Treatment for Women Act: R&D tax credit provisions H.R. 1032, Heart Disease Education, Analysis Research, and Treatment for Women Act: clinical trial data reporting issues H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness H.R. 2751, FDA Food Safety Modernization Act: importation H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, health reform fee, Independent Payment Advisory Board (IPAB) and other health reform implementation issues H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: 340B program issues H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act: transparency of drug pricing H.R. 4872, Health Care and Education Reconciliation Act of 2010: health reform fee issues H.R. 4994, Medicare and Medicaid Extenders Act of 2010: 340B program and other health care issues H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances S. 510, FDA Food Safety Modernization Act: importation S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1203, Grow Research Opportunities With Taxcredits' Help Act: R&D tax credit provisions S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1679, Affordable Health Choices Act: importation, and other health reform implementation issues S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances General FDA advocacy Biopharmaceutical innovation policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| DAVID BOYER | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS New | — |
| ANDREA JEAN DOUGLAS | — |
| DANIEL DURHAM | — |
| LEA FISHER | — |
| JAMES BRYANT HALL | — |
| VALERIE HARDIN JEWETT | — |
| ANN KAPLAN | — |
| HALLIE AMANDA MARANCHICK | — |
| KENDRA MARTELLO | — |
| TOM MOORE | — |
| BRIAN NAGLE | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| RICHARD SMITH | — |
| HEATHER STRAWN | — |
| MATTHEW L SULKALA | — |
| JENNIFER ANNE SWENSON | — |
Medicare/Medicaid MMM
H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, Part D coverage gap discounts, Part D issues generally, Medicare payment issues including the Independent Payment Advisory Board (IPAB), and Medicaid issues H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: non-interference provisions H.R. 4872, Health Care and Education Reconciliation Act of 2010: Part D coverage gap discounts, Part D issues generally, Medicaid rebate issues, health reform fee, and other health reform implementation issues generally H.R. 4994: Medicare and Medicaid Extenders Act of 2010: exclusion issues H.R. 6130 Strengthening Medicare Anti-Fraud Measures Act of 2010: exclusion issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| DAVID BOYER | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS New | — |
| ANDREA JEAN DOUGLAS | — |
| DANIEL DURHAM | — |
| LEA FISHER | — |
| GREGORY GIERER | — |
| JAMES BRYANT HALL | — |
| VALERIE HARDIN JEWETT | — |
| ANN KAPLAN | — |
| TOM MOORE | — |
| BRIAN NAGLE | — |
| LORI REILLY | — |
| RICHARD SMITH | — |
| HEATHER STRAWN | — |
| MATTHEW L SULKALA | — |
| JENNIFER ANNE SWENSON | — |
| STEVE TILTON | — |
Budget/Appropriations BUD
H.R. 3082, Continuing Appropriations Amendments, 2011: FDA funding, comparative effectiveness funding, importation policy rider, Biomedical Advanced Research and Development Authority (BARDA), trade and intellectual property restrictions, patent settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| DAVID BOYER | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS New | — |
| ANDREA JEAN DOUGLAS | — |
| LEA FISHER | — |
| VALERIE HARDIN JEWETT | — |
| TOM MOORE | — |
| BRIAN NAGLE | — |
| LORI REILLY | — |
| RICHARD SMITH | — |
| MATTHEW L SULKALA | — |
| STEVE TILTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.